Compare ROCK & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROCK | DRTS |
|---|---|---|
| Founded | 1972 | 2015 |
| Country | United States | Israel |
| Employees | 2221 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2021 |
| Metric | ROCK | DRTS |
|---|---|---|
| Price | $47.45 | $14.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 199.2K | ★ 611.0K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,135,501,000.00 | N/A |
| Revenue This Year | $41.26 | N/A |
| Revenue Next Year | $20.14 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.56 | $3.43 |
| 52 Week High | $75.08 | $15.17 |
| Indicator | ROCK | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 60.41 |
| Support Level | $38.07 | $6.47 |
| Resistance Level | $51.86 | $14.93 |
| Average True Range (ATR) | 1.75 | 0.59 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 80.52 | 80.26 |
Gibraltar Industries Inc manufactures and provides products and services for the Renewable energy, Residential, Agtech, and Infrastructure markets. The Renewable Segment is engaged in designing, engineering, manufacturing, and installing solar racking and electrical balance systems. Agtech Segment provides growing and processing solutions including the designing, engineering, manufacturing, full-scope construction, maintenance, and support of greenhouses and indoor growing operations, and botanical extraction systems. It derives key revenue from the Residential segment which offers roof and foundation ventilation products, single point and centralized mail systems electronic package solutions, and Retractable awnings and gutter guards, among other products.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.